5α-还原酶抑制剂联合多西他赛在前列腺癌治疗中的疗效分析

Therapeutic Efficacy of 5α-reductase Inhibitor Combined with Docetaxel in the Treatment of Prostate Cancer

目的研究5α-还原酶抑制剂联合多西他赛在前列腺癌治疗中的疗效,为临床用药提供新方案。方法对前列腺癌患者68例,采用手术去势后内分泌联合化疗治疗。根据去势后所用药物的不同分为观察组和对照组。观察组采用5α-还原酶抑制剂(非那雄胺)联合多西他赛,对照组采用比卡鲁胺联合多西他赛。结果与对照组相比,治疗组治疗期间总有效率明显提高(P<0.05),PSA均在正常范围内,排尿梗阻和骨痛症状改善更为明显(P<0.05),各时间点KPS评分均显著增高(P<0.05),无进展生存时间和中位生存期也都明显提高(P<0.05),差异均具有显著性。结论5α-还原酶抑制剂联合多西他赛治疗前列腺癌疗效显著,值得临床推广。

Objective To evaluate the therapeutic efficacy of 5α-reductase inhibitor combined with docetaxel in the treatment of prostate cancer,and provide new solution for clinical medication. Methods 68 patients with prostate cancer who met the adoption standard were selected. After castration operation,the endocrine combined chemotherapy was used for treatment. The patients were divided into the observation group and the control group according to the different drugs used after operation. The observation group was given 5α-reductase inhibitor combined with docetaxel,while the control group was given bicalutamide combined with docetaxel. Results Compared with the control group,the total effective rate during treatment in the observation group significantly increased（ P 〈 0. 05）,PSA level were within the normal range,urination obstruction and bone pain were improved more significantly（ P 〈 0. 05）,KPS scores in different times were significantly increased（ P 〈 0. 05）,and progression-free survival time and median survival time also increased obviously（ P 〈 0. 05）,so all differences were significant. Conclusion 5α-reductase inhibitor combined with docetaxel has a significant therapeutic efficacy on prostate cancer treatment,which is worthy of popularizing in clinical application.